Logo image of TOI

ONCOLOGY INSTITUTE INC/THE (TOI) Stock Fundamental Analysis

NASDAQ:TOI - Nasdaq - US68236X1000 - Common Stock - Currency: USD

2.675  -0.1 (-3.78%)

After market: 2.65 -0.02 (-0.93%)

Fundamental Rating

2

Taking everything into account, TOI scores 2 out of 10 in our fundamental rating. TOI was compared to 102 industry peers in the Health Care Providers & Services industry. TOI has a bad profitability rating. Also its financial health evaluation is rather negative. TOI is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year TOI has reported negative net income.
TOI had a negative operating cash flow in the past year.
TOI had negative earnings in 4 of the past 5 years.
TOI had negative operating cash flow in 4 of the past 5 years.
TOI Yearly Net Income VS EBIT VS OCF VS FCFTOI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

TOI has a Return On Assets of -30.69%. This is amonst the worse of the industry: TOI underperforms 87.25% of its industry peers.
Looking at the Return On Equity, with a value of -1476.73%, TOI is doing worse than 87.25% of the companies in the same industry.
Industry RankSector Rank
ROA -30.69%
ROE -1476.73%
ROIC N/A
ROA(3y)-21.03%
ROA(5y)-18.04%
ROE(3y)-531.94%
ROE(5y)-331.43%
ROIC(3y)N/A
ROIC(5y)N/A
TOI Yearly ROA, ROE, ROICTOI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

1.3 Margins

The Gross Margin of TOI (13.73%) is worse than 68.63% of its industry peers.
TOI's Gross Margin has declined in the last couple of years.
TOI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 13.73%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.94%
GM growth 5Y-6.53%
TOI Yearly Profit, Operating, Gross MarginsTOI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20

More info and screens

2

2. Health

2.1 Basic Checks

TOI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TOI has more shares outstanding
TOI has more shares outstanding than it did 5 years ago.
TOI has a worse debt/assets ratio than last year.
TOI Yearly Shares OutstandingTOI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
TOI Yearly Total Debt VS Total AssetsTOI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of 0.70, we must say that TOI is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of TOI (0.70) is worse than 75.49% of its industry peers.
A Debt/Equity ratio of 25.95 is on the high side and indicates that TOI has dependencies on debt financing.
TOI's Debt to Equity ratio of 25.95 is on the low side compared to the rest of the industry. TOI is outperformed by 86.27% of its industry peers.
Industry RankSector Rank
Debt/Equity 25.95
Debt/FCF N/A
Altman-Z 0.7
ROIC/WACCN/A
WACC7.86%
TOI Yearly LT Debt VS Equity VS FCFTOI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

TOI has a Current Ratio of 2.15. This indicates that TOI is financially healthy and has no problem in meeting its short term obligations.
TOI has a better Current ratio (2.15) than 76.47% of its industry peers.
TOI has a Quick Ratio of 1.96. This is a normal value and indicates that TOI is financially healthy and should not expect problems in meeting its short term obligations.
With a decent Quick ratio value of 1.96, TOI is doing good in the industry, outperforming 74.51% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.15
Quick Ratio 1.96
TOI Yearly Current Assets VS Current LiabilitesTOI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

7

3. Growth

3.1 Past

The Revenue has grown by 28.41% in the past year. This is a very strong growth!
TOI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 23.43% yearly.
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.73%
Revenue 1Y (TTM)28.41%
Revenue growth 3Y20.03%
Revenue growth 5Y23.43%
Sales Q2Q%10.29%

3.2 Future

TOI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 32.88% yearly.
The Revenue is expected to grow by 22.73% on average over the next years. This is a very strong growth
EPS Next Y38.52%
EPS Next 2Y32.88%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year29.38%
Revenue Next 2Y22.73%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
TOI Yearly Revenue VS EstimatesTOI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M
TOI Yearly EPS VS EstimatesTOI Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 -0.2 -0.4 -0.6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TOI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TOI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TOI Price Earnings VS Forward Price EarningsTOI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TOI Per share dataTOI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

A more expensive valuation may be justified as TOI's earnings are expected to grow with 32.88% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.88%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

TOI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ONCOLOGY INSTITUTE INC/THE

NASDAQ:TOI (5/21/2025, 4:37:06 PM)

After market: 2.65 -0.02 (-0.93%)

2.675

-0.1 (-3.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)08-11 2025-08-11
Inst Owners39.66%
Inst Owner Change12.67%
Ins Owners2.87%
Ins Owner Change14.2%
Market Cap234.76M
Analysts84
Price TargetN/A
Short Float %1.98%
Short Ratio1.47
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-8.54%
Min Revenue beat(2)-9.05%
Max Revenue beat(2)-8.03%
Revenue beat(4)0
Avg Revenue beat(4)-6.03%
Min Revenue beat(4)-9.05%
Max Revenue beat(4)-1.51%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.6
P/FCF N/A
P/OCF N/A
P/B 65.41
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.69
EYN/A
EPS(NY)-0.16
Fwd EYN/A
FCF(TTM)-0.35
FCFYN/A
OCF(TTM)-0.3
OCFYN/A
SpS4.48
BVpS0.04
TBVpS-0.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.69%
ROE -1476.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 13.73%
FCFM N/A
ROA(3y)-21.03%
ROA(5y)-18.04%
ROE(3y)-531.94%
ROE(5y)-331.43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.94%
GM growth 5Y-6.53%
F-Score3
Asset Turnover2.28
Health
Industry RankSector Rank
Debt/Equity 25.95
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 60.27%
Cap/Sales 0.96%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.15
Quick Ratio 1.96
Altman-Z 0.7
F-Score3
WACC7.86%
ROIC/WACCN/A
Cap/Depr(3y)87.81%
Cap/Depr(5y)78.43%
Cap/Sales(3y)1.52%
Cap/Sales(5y)1.34%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.73%
EPS Next Y38.52%
EPS Next 2Y32.88%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)28.41%
Revenue growth 3Y20.03%
Revenue growth 5Y23.43%
Sales Q2Q%10.29%
Revenue Next Year29.38%
Revenue Next 2Y22.73%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y0.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year107.61%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y25.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.92%
OCF growth 3YN/A
OCF growth 5YN/A